Finland· FI-REL-REL56002
Ryaltris
A mometason, kombinationen product containing olopatadine hydrochloride + mometasone furoate monohydrate, registered in Finland by Glenmark Pharmaceuticals s.r.o.. The same ATC class is registered in 10 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Mometason, kombinationen is registered in 10 of 19 countries.
Countries holding a registration under ATC R01AD59 (mometason, kombinationen), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 6 of them publish a price we can compare per daily dose
Mometason, kombinationen · ATC R01AD59
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Olopatadine hydrochloride + Mometasone furoate monohydrate
- Manufacturer
- Glenmark Pharmaceuticals s.r.o.
- Country
- Finland (FI)
- ATC code
- R01AD59
- ATC class
- Mometason, Kombinationen
- Defined daily dose
- 0.2 mg, N
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mometason, kombinationen in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandRyaltrisInPharm Sp. z o.o.
- NetherlandsRyaltris 25/600 microgram/dosis neusspray, suspensieGlenmark Pharmaceuticals s.r.o.
- CzechiaRYALTRISGlenmark Pharmaceuticals s.r.o., Praha
- SwitzerlandRyaltris 25 μg / 600 μg, Nasenspray, SuspensionNOBEL Pharma Schweiz AG
- United StatesRyaltrisHIKMA SPECIALTY USA INC.
- SwedenMometasone furoate/Olopatadine Glenmark 25 mikrogram/dos + 600 mikrogram/dos Nässpray, suspensionGlenmark Arzneimittel GmbH
- United KingdomRyaltris 25micrograms/dose / 600micrograms/dose nasal sprayNecessity Supplies Ltd
- IrelandRyaltris 25 microgram/actuation + 600 microgram/actuation nasal spray, suspensionGlenmark Pharmaceuticals s.r.o.
Authorised across Europe · EMA
The same active substance is authorised in 20 EEA countries. Names it is sold under:
- Austria · Ryaltris
- Belgium · Ryaltris
- Czechia · Ryaltris
- Germany · Ryaltris
- Denmark · Ryaltris
- Spain · Ryaltris
- France · Ryaltris
- United Kingdom (Northern Ireland) · Ryaltris
- Ireland · Ryaltris
- Italy · Rineffix, Ryaltris
- Lithuania · Ryaltris
- Luxembourg · Ryaltris
- Latvia · Ryaltris
- Malta · Ryaltris
- Netherlands · Ryaltris
- Norway · Ryaltris
- Poland · Ryaltris
- Romania · Ryaltris
- Sweden · Mometasone Furoate/Olopatadine Glenmark, Ryaltris
- Slovakia · Ryaltris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/45b01fbe-d51a-4f9a-9989-7f2c9cbd2e06 GET /v1/drugs/45b01fbe-d51a-4f9a-9989-7f2c9cbd2e06?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "8",
"form": "nenäsumute, suspensio",
"route": "Nenään",
"ddd_unit": "ED",
"strength": "25 mikrogrammaa / annos + 600 mikrogrammaa / annos",
"atc_label": "mometasoni, yhdistelmävalmisteet",
"ma_number": "37787",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL56002",
"authorised_at": "2021-05-27"
}See everything about mometason, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.